Arena Pharmaceuticals ARNA announces its next round of earnings Monday. Here is Benzinga's everything-that-matters guide for the Q2 earnings announcement.
Earnings and Revenue
Based on Arena Pharmaceuticals management projections, analysts predict an EPS loss of 64 cents on revenue of $2.91 million.
Arena Pharmaceuticals EPS loss in the same period a year ago came in at 77 cents. Sales were $6.49 million. Revenue would be down 55.18 percent on a year-over-year basis. Here's how the company's EPS has stacked up against analyst estimates in the past:
Quarter | Q1 2018 | Q4 2017 | Q3 2017 | Q2 2017 |
EPS Estimate | -0.68 | -0.59 | -0.67 | -0.74 |
EPS Actual | -0.78 | -0.36 | -0.55 | -0.77 |
Stock Performance
Over the last 52-week period, shares are up 56.6 percent. Given that these returns are generally positive, long-term shareholders should be content going into this earnings release. Over the past 90 days, analysts have generally adjusted their estimates higher for EPS and revenues. The most common rating from analysts on Arena Pharmaceuticals stock is a Neutral. The strength of this rating has maintained conviction over the past three months.
Conference Call
Arena Pharmaceuticals' Q2 is scheduled to hold a conference call at 4:30 p.m. ET and it can be accessed here: http://invest.arenapharm.com/events-presentations
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.